TY - JOUR
T1 - New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study
AU - Klikovits, Thomas
AU - Lohinai, Zoltán
AU - Fábián, Katalin
AU - Gyulai, Márton
AU - Szilasi, Mária
AU - Varga, Judit
AU - Baranya, Erika
AU - Pipek, Orsolya
AU - Csabai, Istvan
AU - Szallasi, Zoltan
AU - Tímár, József
AU - Hoda, Mir Alireza
AU - Laszlo, Viktoria
AU - Hegedűs, Balázs
AU - Renyi-Vamos, Ferenc
AU - Klepetko, Walter
AU - Ostoros, Gyula
AU - Döme, Balázs
AU - Moldvay, Judit
PY - 2018
Y1 - 2018
N2 - Introduction: The presence of organ metastases is a major factor for unfavorable prognosis in lung adenocarcinoma (LADC). However, the influence of primary tumor location on metastatic sites and sequence has not been extensively analyzed.
Methods: We performed a multicenter cohort study, evaluating clinicopathological data of 1126 Caucasian LADC patients, focusing on the distinct location of primary tumors and metastatic sites during disease progression.
Results: Metastases to the lung (p < 0.001), pleura (p < 0.001) and adrenal glands (p < 0.001) occurred earlier during disease progression and central primary tumors were associated with early metastases (OR 1.43, p = 0.02). In secondary exploratory analysis we found that bone metastases were more frequent in patients with central tumors (OR 1.86, p = 0.017), whereas lung metastases in those with peripheral tumors (OR 1.35, p = 0.015). Central primary LADCs were associated with decreased median overall survival (vs. peripheral tumors, 10.2 vs. 22 months) both in univariate (HR 2.075, p = 0.001) and in multivariate (HR 1.558, p < 0.001) analyses and independent from stage and T factor. By subsequent analysis, we found that bone metastases tend to appear together with adrenal and liver metastases, and adrenal with skin, and pleural with pericardial metastases more frequently than expected if metastatic events occurred independently.
Conclusion: This comprehensive large cohort analysis demonstrates metastatic site- and sequence-specific variations in patients with LADC. Central LADC is associated with early metastatic disease, bone involvement and, consequently, decreased survival.
AB - Introduction: The presence of organ metastases is a major factor for unfavorable prognosis in lung adenocarcinoma (LADC). However, the influence of primary tumor location on metastatic sites and sequence has not been extensively analyzed.
Methods: We performed a multicenter cohort study, evaluating clinicopathological data of 1126 Caucasian LADC patients, focusing on the distinct location of primary tumors and metastatic sites during disease progression.
Results: Metastases to the lung (p < 0.001), pleura (p < 0.001) and adrenal glands (p < 0.001) occurred earlier during disease progression and central primary tumors were associated with early metastases (OR 1.43, p = 0.02). In secondary exploratory analysis we found that bone metastases were more frequent in patients with central tumors (OR 1.86, p = 0.017), whereas lung metastases in those with peripheral tumors (OR 1.35, p = 0.015). Central primary LADCs were associated with decreased median overall survival (vs. peripheral tumors, 10.2 vs. 22 months) both in univariate (HR 2.075, p = 0.001) and in multivariate (HR 1.558, p < 0.001) analyses and independent from stage and T factor. By subsequent analysis, we found that bone metastases tend to appear together with adrenal and liver metastases, and adrenal with skin, and pleural with pericardial metastases more frequently than expected if metastatic events occurred independently.
Conclusion: This comprehensive large cohort analysis demonstrates metastatic site- and sequence-specific variations in patients with LADC. Central LADC is associated with early metastatic disease, bone involvement and, consequently, decreased survival.
KW - Lung adenocarcinoma
KW - Metastases
KW - Primary tumor location
KW - Survival
KW - Metastatic sites
U2 - 10.1016/j.lungcan.2018.11.004
DO - 10.1016/j.lungcan.2018.11.004
M3 - Journal article
C2 - 30527178
SN - 0169-5002
VL - 126
SP - 139
EP - 148
JO - Lung Cancer
JF - Lung Cancer
ER -